Differential gene-expression profiles associated with gastric adenoma by Takenawa, H et al.
Differential gene-expression profiles associated with gastric
adenoma
H Takenawa
1, M Kurosaki
1,2, N Enomoto*,1, Y Miyasaka
1, N Kanazawa
1, N Sakamoto
1, T Ikeda
3, N Izumi
2,
C Sato
4 and M Watanabe
1
1Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan;
2Department of Gastroenterology and
Hepatology, Musashino Red Cross Hospital, Tokyo, Japan;
3Department of Internal Medicine, Yokosuka Kyousai Hospital, Kanagawa, Japan;
4Department of Health Science, Tokyo Medical and Dental University, Tokyo, Japan
Gastric adenomas may eventually progress to adenocarcinomas at varying rates. The purpose of the present study was to identify
gene-expression profiles linked to the heterogeneous nature of gastric adenoma as compared to adenocarcinoma. Suppression
subtractive hybridisation analysis was performed to extract relevant genes from two cases of low- and high-grade gastric adenomas.
The identified genes were quantified by RT–PCR in 14 low-grade adenoma, nine high-grade adenoma and nine adenocarcinoma
samples, followed by hierarchical clustering analysis to separate tumours into groups according to their gene-expression profiles. Nine
genes previously implicated in carcinogenesis in a variety of organs, including three genes related to gastric adenocarcinoma, were
identified. The overexpression of these genes in gastric adenoma has not been reported previously. The clustering analysis of these
nine genes across 32 cases identified three groups, one of which consisted primarily of adenocarcinomas, whereas the other two
groups consisted of adenomas. One group of adenomas, characterised by larger tumour size, exhibited gene-expression profiles of an
intestinal cell lineage implicated in the pathogenesis of an intestinal-type gastric adenocarcinoma. Another adenoma group consisting
of low-grade adenomas with smaller tumour size exhibited a unique expression profile. In conclusion, clustering analysis of expression
profiles using a limited number of genes may serve as molecular markers for gastric adenoma with different biological properties.
Although the prognostic values of these gene-expression profiles need to be evaluated in further follow-up study of adenoma cases,
these findings add new insights to (a) our understanding of the pathogenesis of gastric tumours, (b) the development of specific
tumour markers for clinical practice, and (c) the design of novel therapeutic targets.
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Gastric adenomas are considered to be precancerous lesions, but
are clinically heterogeneous, since some may progress to
adenocarcinoma, whereas others persist unchanged for long
periods (Kamiya et al, 1982; Kolodziejczyk et al, 1994; Orlowska
et al, 1995). Identification of adenoma cases with a progressive
nature is important since intervention (e.g. endoscopic mucosal
resection) is mandatory. Tumour size is a prognostic indicator, but
exceptional cases are frequently observed. Histological grading of
adenomas as per the Vienna classification (Schlemper et al, 2000)
has been used to assess the potential for progression. However,
exceptional cases are frequent, since 80% of high-grade adenomas
progress to adenocarcinomas, whereas 15% of low-grade adeno-
mas progress to high-grade adenomas or adenocarcinomas
(Lauwers and Riddell, 1999). Histological diagnosis of biopsy
specimens cannot definitively identify adenomas with aggressive
potential because sampling errors may contribute to the under-
estimation of tumour grade or depth of invasion. Thus, an
additional prognostic indicator that is independent of conven-
tional clinicopathological findings (e.g. molecular markers) is
essential.
Recent comprehensive analyses of gene expression, such as a
microarray analysis, identified relevant genes whose expression
profiles appeared to be linked to tumour stage, histological grade,
susceptibility to chemotherapy, clinical aggressiveness or prog-
nosis (Golub et al, 1999; Alizadeh et al, 2000; Perou et al, 2000;
Dhanasekaran et al, 2001; Sorlie et al, 2001; Shipp et al, 2002; van’t
Veer et al, 2002). Studies on gastric adenocarcinomas revealed
several gene-expression profiles that are linked to lymph node
metastasis (Hasegawa et al, 2002; Hippo et al, 2002). Using a
similar approach, it may be possible to develop an improved
classification scheme for gastric tumours that is capable of
distinguishing subgroups of adenomas with progressive natures.
Such expression profiles have not been applied to gastric
adenomas. In the present study, suppression subtractive hybridi-
zation (SSH) analysis (Diatchenko et al, 1996; von Stein et al, 1997)
was used to identify genes relevant to gastric adenomas. Their
expression profiles were subsequently assessed in order to identify
different progressive potentials of gastric adenomas in comparison
to adenocarcinoma.
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Tissue sample
Tissue samples of low-grade (6mm in diameter) and high-grade
(15mm in diameter) gastric adenomas and adjacent gastric
mucosa were obtained from 68- and 44-year-old male
subjects, respectively, by endoscopic mucosal resection for use in
SSH analysis. Additional paired tissue samples of gastric
tumours and adjacent mucosa were obtained by endoscopic
biopsy or mucosal resection from 14 low-grade adenomas, nine
high-grade adenomas and nine adenocarcinomas for gene-expres-
sion profiles (Table 1). The nine adenocarcinomas consisted of six
T1, two T2 and one T3 tumours based on TNM clinical
classification. Histopathological grading was G1 in seven cases
and G2 in two cases. Tumour size was significantly different
among the low- and high-grade adenomas and the adenocarcino-
mas. Informed consent was obtained from each patient before
biopsy or mucosal resection. The study conformed to the
ethical guidelines of the 1975 Declaration of Helsinki and was
approved by the IRB.
RNA extraction and SMARTt cDNA synthesis
Total RNA was extracted by the modified acid–guanidium–
chloroform method (Chomczynski and Sacchi, 1987) using
ISOGENt (Nippon Gene, Toyama, Japan). Full-length cDNAs
were generated from the total RNA using the SMARTt (Switch
Mechanism at 50 end of RNA Template) PCR cDNA synthesis kit
(Clontech, Palo Alto, CA, USA) (Matz et al, 1999) following the
manufacturer’s instruction and used for SSH analysis. Quantitative
analysis of specific genes was performed on cDNAs generated from
1mg of total RNA in 10ml mixture with 200U of Superscriptt
reverse transcriptase (Gibco, Madison, WI, USA) using random
hexamer primers.
Suppression SSH and sequencing
Subtractive hybridization was performed using a PCR-Selectt
cDNA subtraction kit (CLONTECH, Tokyo, Japan) according to
the manufacturer’s instructions. Briefly, after two different
adaptors were ligated to RsaI-digested SMARTt cDNA from the
gastric adenoma tissues (tester), 2.5ng of each adaptor-ligated
SMARTt cDNA was hybridised with 1.5mgo fRsaI-digested
SMARTt cDNA from the adjacent gastric mucosa (driver). In this
process, cDNA sequences specific to the tester were enriched. A
total of 10ng of PCR products were cloned into plasmids pGEM-T
Easy Vectort (Stratagene, Cedar Creek, TX, USA) and transformed
to competent Escherichia coli XL2-bluet Ultracompetent cells
(Gibco, Madison, WI, USA). In all, 100 colonies were randomly
picked and sequenced using the PRISM dye termination kitt (ABI,
Chiba, Japan). BLAST Search 2.0 (www.ncbi.nlm.nih.gov/blast/
blast.cgi) was used to analyse sequence homologies in the gene
database.
Quantitative analysis of identified genes
Overexpression of genes identified by SSH was verified in the
original samples by semiquantitative RT–PCR using gene-specific
primer sets. The PCR products were obtained during the
exponential phase of amplification and the amounts of products
were compared by agarose-gel electrophoresis. Subsequently, the
mRNA expression levels of these genes were quantitated using
real-time PCR (Light Cycler Systemt, Roche Diagnostics, Man-
heim, Germany) (Wittwer et al, 1997). The expression level of the
target gene was standardised with that of the house-keeping beta-
actin gene and the ratio of each gene expression in paired samples
(adenoma or adenocarcinoma/adjacent mucosa) was calculated.
The primers used in the quantitative PCR were as follows: acyl-
CoA binding protein (ACBP)-sense, 50AgTTTgAgAAAgCTgCAg
AggAgg30; ACBP-antisense, 50TCCCgAATTCCCACCATCCACggT30;
eukaryotic elongation factor 1 gamma (EEF1G)-sense, 50TATCg
CTTCCCTgAAgAACTCACT30; EEF1G-antisense, 50TCgCTgCCAgg
ATCCAgTTTCCgC30; peripheral-type benzodiazepine receptor
(BZRP)-sense, 50gCgACCACACTCAACTACTgCgTA30; BZRP-anti-
sense, 50gCATgCAGAAAgCACAggACACTg30; arginase II (ARG2)-
sense, 50gAgACAAAgACCAATCCATTTgA30; ARG2-antisense, 50gT
gTATTTCCTCAgCAATATACAT30; histone H2A.Z (H2AFZ)-sense,
50TggCAggAAATgCATCAAAAgACT30; H2AFZ-antisense, 50ggAA
AgCTAATTAAACTTCCAACT30; GW112-sense, 50gAATCTTCTA
CCTCATAACTTCCT30; GW112-antisense, 50gCAACAACTgATAC
ACTCATAAgT30; pepsinogen C (PGC)-sense, 50CAGCTTGACC
TTCATCATCAATG30; PGC-antisense, 50CCAGAGTGGAAAGACA
GATACAA30; defensin alpha 5 (DEFA5)-sense, 50ATCCTTgCTg
CCATTCTCCTggTg30; DEFA5-antisense, 50ACCTgAggTTCTA
AgAgCAgAgA30; receptor for activated C-kinase (RACK1)-sense,
50AACAgCAAgCAACCCTATCATCgT30; RACK1-antisense, 50gATA
ACTTCTTgCTTCAgTTCATC30; LI-Cadherin (CDH17)-sense,
50AACTTAACgATAgAggTgTCTgAC30; and CDH17-antisense
50gCTTTgAACACAATgTTggAAACA30.
When the expression levels of target genes were below the
sensitivity of the assay, the detection limits for each gene were
substituted to calculate the ratio. The ratio was not determined
when the target gene could not be quantitated in both the paired
samples. For example, the expression level of GW112 was below
the sensitivity of this quantitation system in all samples and,
therefore, this gene was not included in subsequent analyses.
Analysis of gene-expression profiles
Unsupervised hierarchical clustering analysis was performed based
on similarities of gene expression using web-available software
(Expression Profiler; European Bioinformatics Institute; http://
ep.ebi. ac.uk/). The ratio of each gene expression in paired samples
was log transformed and applied to the clustering algorithm.
Statistical analyses
Data were compared using the w
2 test or Fisher’s exact
test. Distributions of continuous data were analysed by the
Table 1 Clinical backgrounds of patients
Adenoma
Low grade (n¼14) High grade (n¼9)
Adenocarcinoma
(n¼9)
a
Age (years) (mean7s.d.) 73.577.6 67.2710.8 76.179.2
Sex (male/female) 13/1 7/2 7/2
Tumour size (mean7s.d.)
b 10.174.0 19.878.3 30.8712.8
aAdenocarcinoma cases included six cases of T1, two cases of T2 and one case of T3 in TNM clinical classification. Histopathological grading was G1 in seven cases and G2 in two
cases.
bPo0.005 for low- vs high-grade adenoma, low-grade adenoma vs adenocarcinoma and Po0.05 for high-grade adenoma vs adenocarcinoma.
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by ANOVA with adjustment for multiple comparison by Scheffe’s
method among three groups using Statview 5.0 software (Abacus
Concepts, Berkeley, CA, USA).
RESULTS
SMARTt RT–PCR and SSH
The cDNA generated by SMARTt RT–PCR exhibited a smear
pattern representing amplification of the whole mRNA species on
agarose-gel electrophoresis, whereas after SSH it consisted of
several discrete bands derived from differentially expressed genes
(Figure 1). Nucleotide sequencing was performed for 100
independent clones for each SSH experiment. Six genes repre-
sented more than once in low-grade adenoma samples: (a) RACK1
(accession number NM_001172), (b) ARG2 (NM_001172), (c)
EEF1G (NM_001404), (d) ACBP (NM_02054), (e) H2AFZ
(NM_00210) and (f) DEFA5 (NM_021010). In addition, five genes
represented more than once in high-grade adenoma samples: (a)
PGC (NM_002630), (b) BZRP (NM_007311), (c) DEFA5, (d)
GW112 (AF097021), and (e) CDH17 (NM_004063) (Table 2).
Defensin alpha 5 was detected in both the SSH samples. All these
genes have been previously implicated in carcinogenesis in
different organs or cell proliferation. These repetitively detected
genes were used for further analysis and the miscellaneous genes
that were detected only once were excluded.
Confirmation of differential gene expression by
semiquantitative RT–PCR
The overexpression of genes in SMART-cDNA samples was
verified by semiquantitative RT–PCR using gene-specific primer
sets. PCR products isolated during the exponential phase of
amplification were analysed by agarose-gel electrophoresis in
order to compare the amount of specific products. The minimal
number of PCR cycles required for visualisation on agarose gels
was selected for each gene. The amount of PCR product at the
same PCR cycle was similar for beta-actin, a representative
housekeeping gene, but those of genes identified by SSH were
clearly more abundant in the gastric adenoma or adenocarcinoma
tissues (Figure 1 in comparison to their corresponding adjacent
gastric mucosa tissues.
Quantification of identified genes
The expression levels of the identified genes were quantified by
quantitative PCR in 14 low-grade adenomas, nine high-grade
adenomas and nine adenocarcinomas, including the original
samples used in SSH analyses (Figure 2). RACK1, ACBP, CDH17
and EEF1G were significantly overexpressed in low-grade adeno-
mas, whereas DEFA5 was significantly overexpressed in high-grade
adenomas and suppressed in adenocarcinomas. These findings
suggest that these genes reflect the molecular features of gastric
tumours with different histological diagnoses, but that individual
analysis of these genes does not define the progressive potential of
gastric tumours.
Analysis of gene-expression profiles using unsupervised
hierarchical clustering
In order to determine if the analysed samples could be classified
into groups on the basis of their gene-expression profiles alone,
hierarchical clustering analysis was performed. The ratio of gene
expression was first log transformed and then applied to the
clustering algorithm. The expression patterns of nine genes across
32 samples are shown in Figure 3. The dendrogram of the 32 cases
at the right of the matrix, in which the pattern and length of
branches reflect the relatedness of the samples, separated samples
into three major groups based on the similarities in gene-
expression profiles.
Clinicopathological factors in relation to clustered groups
In order to clarify the clinical features associated with this
clustering, various clinicopathological factors, including age,
gender, histological diagnosis and tumour size, were analysed.
TN  
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Figure 1 Electrophoretic band patterns of SSH and gene overexpres-
sion in original tester tissue. (A) The cDNA amplified by SMARTt RT–
PCR and cDNA after subtraction by SSH were electrophoresed on 2.0%
agarose. The amplified cDNA derived from gastric adenoma and adjacent
gastric mucosa appears as a smear before SSH. After SSH, it exhibits
several distinct bands. (B) Semiquantitative RT–PCR using gene-specific
primer sets for each identified gene were performed. PCR products were
analysed at the PCR cycle number in the exponential phase of amplification
(ACBP 36 cycles, RACK1 27 cycles, DEFA5 36 cycles, EEF1G 13 cycles,
H2FAZ 30 cycles, ARG2 36 cycles, PGC 25 cycles, BZRP 24 cycles, CDH17
22 cycles, GW112 40 cycles, beta-actin 20 cycles). The expression level of
housekeeping gene (beta-actin) was at the same level, but those of genes
identified by SSH were clearly more abundant in low- and high-grade
gastric adenoma tissues compared to their corresponding adjacent mucosa.
T and N indicate gastric tumour and adjacent normal mucosa, respectively.
Table 2 Genes identified by SSH analysis
Gene Symbol Accession no.
Low-grade adenoma derived
Receptor for activated C-kinase RACK1 NM-006098
Arginase II ARG2 NM-001172
Eukaryotic elongation factor 1 gamma EEF1G NM-001404
Acyl-CoA binding protein ACBP NM-020548
Histone H2A.Z H2AFZ NM-002106
Defensin alpha 5 DEFA5 NM-021010
High-grade adenoma derived
Pepsinogen C PGC NM-002630
Peripheral-type benzodiazepine receptor BZRP NM-007311
Defensin alpha 5 DEFA5 NM-021010
GW112 GW112 AF097021
LI-Cadherin CDH17 NM-004063
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nomas were significantly different among the three groups
(Po0.05) (Table 3). The first group consisted of six low-grade
and three high-grade adenomas; the second group consisted of six
low-grade and five high-grade adenomas and an adenocarcinoma;
the third group consisted of eight adenocarcinomas, two low-grade
adenomas and two high-grade adenomas. Three cases of
adenocarcinoma in advanced tumour stage (T2 or T3 in TNM
classification) and two cases with moderately differentiated
adenocarcinoma (G2) clustered into the third group. When
adenomas and adenocarcinomas were analysed together, tumour
size became significant in the order of groups 1–3. The tumour
size of adenomas was significantly small in group 1 in comparison
to group 2 or to groups 2 and 3 collectively. When low- and high-
grade adenomas were compared separately, the tumour size of
low-grade adenomas in group 1 was significantly smaller in
comparison to those in group 2 or in groups 2 and 3 collectively.
High-grade adenomas in group 1 were smaller than those in group
2 or in groups 2 and 3 collectively, although the difference was not
statistically significant (Figure 4).
Gene-expression profiles with respect to clustered groups
In order to investigate the gene-expression profiles responsible for
this clustering, the expression levels of each gene were compared
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Figure 3 Hierarchical clustering analysis. The expression patterns of nine
genes across 32 samples are shown. Each column indicates a gene, and
each row indicates a sample. Red and green indicate the overexpression
and underexpression, respectively, of genes in adenomas or adenocarci-
nomas in comparison to the adjacent mucosa. Graduated colour patterns
correspond to the degrees of expression changes. Black colour indicates
that the expression was not detected in both the paired samples. The
dendrogram of the 32 cases at the right of the matrix, in which the pattern
and length of branches reflect the relatedness of the samples, indicates that
the samples are clustered into three major branches based on the similarity
of gene-expression profiles. The abbreviations Low, High and Ca stand for
low-grade adenoma, high-grade adenoma and adenocarcinoma, respec-
tively.
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Figure 2 Expression levels of identified genes in 32 cases. The
expression levels of nine genes in 14 low-grade adenomas, nine high-
grade adenomas and nine adenocarcinomas are shown as the mean and
95% confidence interval. Data for ACBP in adenocarcinomas were not
available for analysis due to the small number of cases. RACK1, ACBP,
CDH17 and EEF1G were significantly overexpressed in low-grade
adenoma; DEFA5 was significantly overexpressed in high-grade adenoma
and suppressed in adenocarcinoma.
Table 3 Clinical backgrounds of all cases categorised into three groups by cluster analysis
Group-1 (n¼9) Group-2 (n¼11) Group-3 (n¼12)
Age (years) (mean7s.d.) 69.4710.7 68.977.1 78.078.1
Sex (male/female) 9/0 9/2 9/3
Histological diagnosis
a 6/3/0 6/4/1 2/2/8
Tumor size (mean7s.d.)
b 9.374.3 16.477.6 27.7713.1
Adenoma
c 9.374.3 16.278.0 18.378.9
Adenocarcinoma (adenocarcinoma cases only) 18.0 32.4712.7
TNM clinical classification (T1/T2 or T3) 1/0 5/3
Histological differentiation (G1/G2) 1/0 6/2
aLow-grade adenoma/high-grade adenoma/adenocarcinoma according to Vienna classification. Po0.05.
bPo0.001 for group-1 vs 3 and Po0.05 for group-1 vs 2, group-2 vs 3.
cPo0.05 for group-1 vs 2 and for group 1 vs groups 2 and 3 collectively (16.878.0).
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The expression levels of ACBP, PGC and RACK1 were significantly
higher in group 1 in comparison to group 2 and/or group 3 (ACBP:
Po0.05 for 1 vs 2; PGC: Po0.001 for 1 vs 2, Po0.005 for 1 vs 3;
RACK1: Po0.05 for 1 vs 2 and 1 vs 3). In contrast, the expression
levels of CDH17 and DEFA5 were significantly higher in group 2 in
comparison to groups 1 or 3 (CDH17: Po0.005 1 vs 2 and 2 vs 3;
and DEFA5: Po0.0001 for 2 vs 3 and Po0.0005 for 1 vs 3). Only
ARG2 exhibited a high level of expression in group 3 (Po0.05 for 2
vs 3, Po0.01 for 1 vs 2). The hierarchical clustering analysis using
these six genes resulted in clusters identical to that using nine
genes (data not shown). The plot of the log-transformed ratio of
these genes is shown in Figure 5.
DISCUSSION
In the present study, we identified nine genes specifically
overexpressed in low- and high-grade gastric adenomas. Although
these genes have been implicated in carcinogenesis in a variety of
organs, the overexpression of these genes in gastric adenomas has
not been investigated previously. Unsupervised clustering analysis
of expression profiles using these gastric adenoma-related genes
was performed in a total of 32 gastric adenomas and adenocarci-
nomas, resulting in a classification with a close correlation to
histological stages. Moreover, the adenomas were further divided
into two subgroups with different tumour sizes according to their
expression profiles. These results suggest that expression profiles
may be linked to different biological properties of gastric
adenomas or adenocarcinomas.
Analysis of the nine adenoma-related genes in 32 cases of gastric
tumours demonstrated that a portion of the genes exhibited
significantly increased expressions in adenomas, whereas none of
these genes was overexpressed in adenocarcinomas (Figure 2).
This suggests that these genes play a specific role in the
development of adenomas, but that their expression levels were
variable in these tumours. This observation raises the possibility
that the molecular nature of gastric adenomas is heterogeneous
and separate analyses of individual genes are not informative.
Accordingly, we tried to classify gastric tumours using gene-
expression profiling.
Three distinct groups of gastric tumours were identified by an
unsupervised hierarchical clustering analysis of expression
profiles of nine adenoma-related genes. A search for clinicopatho-
logical features linked to this classification revealed that
these three groups differed significantly in their constitutive
proportions of low- and high-grade adenomas or adenocarcino-
mas. One group consisted predominantly of adenocarcinomas
(group 3) into which all advanced clinical stage or histological
grade adenocarcinomas were classified, suggesting that expression
profiles successfully distinguished gastric adenocarcinomas from
adenomas.
The other two groups (groups 1 and 2) consisted of mixtures of
low- and high-grade adenomas. Group 1 adenomas were
significantly smaller than group 2 tumours, demonstrating that
the expression profiles differentiate gastric adenomas into two
subgroups with potentially different biological properties unde-
tected by conventional histopathological classification. We suggest
that gene-expression profiles not only confirm major histologic
distinctions between gastric adenomas and adenocarcinomas but
may also define subgroups of gastric adenomas with different
biological natures.
Group 1, consisting of small adenomas with a slightly increased
proportion of low-grade cases and no adenocarcinomas, exhibited
expression profiles characterised by three overexpressed genes,
that is, RACK1, PGC and ACBP. RACK1, previously known as G
protein beta-subunit-like protein 12.3, is a signal molecule
involved in the MAPK pathway through binding to Src, integrin
beta-subunit or interferon receptor (Chang et al, 1998; Liliental
and Chang, 1998; Croze et al, 2000; Kiely et al, 2002). Pepsinogen C
is the precursor of pepsin C that is expressed in the normal gastric
mucosa, and is also involved in gastric epithelial cell growth during
mucosal healing (Kishi et al, 1997). Acyl-CoA binding protein is
involved in steroid biosynthesis and in the stimulation of cell
proliferation (Papadopoulos, 1993). Although these genes are
related to cell proliferation and their overexpression has been
reported in tumours of different organs, their association with
gastric adenocarcinomas has not been confirmed (Diez-Itza et al,
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clustering analysis. Open circles denote low-grade adenomas, grey circles
denote high-grade adenomas and closed circles denote adenocarcinomas.
Tumour size was significantly larger in group 3 in comparison to groups 1 or
2 and significantly larger in group 2 vs group 1. When a comparison was
made independent of histological diagnosis, tumour size of low-grade
adenomas was significantly smaller in group 1 in comparison to group 2 or
to groups 2 and 3 collectively (Po0.05). High-grade adenoma in group 1
also tended to be smaller than those in group 2 or groups 2 and 3 in
combination, although the differences did not reach statistic significance
(P¼0.09 for group 1 vs 2 and P¼0.10 for group 1 vs groups 2 and 3
collectively).
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Figure 5 Plot of the gene-expression ratio according to groups
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expression levels of ACBP, PGC and RACK1 were significantly high in group
1 compared to group 2 and/or group 3. In contrast, the expression levels of
CDH17 and DEFA5 were significantly high in group 2 compared to group 1
or group 3. Only ARG2 showed a high level of expression in group 3. *1
Po0.05, *2 Po0.01, and *3 Po0.005.
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Venturini et al, 1999; Berns et al, 2000; Miyasaka et al, 2001; Saito
et al, 2002). In the present study, the expression of these genes did
not increase in either group 2, the larger adenomas or group 3, the
adenocarcinomas. These genes may play a role in the pathogenesis
of gastric adenomas in their early stages or in more benign
courses, that is, a limited role in the progression to adenocarci-
noma.
In comparison, group 2, a mixture of larger low- and high-grade
adenomas, as well as one adenocarcinoma, was characterised by
the overexpression of two intestine-specific genes, CDH17 and
DEFA5. LI-Cadherin is usually expressed in normal intestinal
mucosa and ectopically in well-differentiated gastric adenocarci-
nomas (Grotzinger et al, 2001). Defensin alpha 5 consists of a
family of antimicrobial peptides that are highly expressed in small
intestinal Paneth cells (Inada et al, 2001). The defensin family has
alternative functions, such as promotion of cell differentiation
(Frye et al, 2001). It is also known to be overexpressed in cancers
of the kidney and oral mucosa (Muller et al, 2002). The intestine-
specific transcription factor, CDX2, has recently been implicated in
the regulation of CDH17 and DEFA5 (Eda et al, 2002; Hinoi et al,
2002). In the normal small intestine, CDX2 controls the expression
of genes that determine the cellular lineage of the small intestinal
epithelium. The ectopical expression of CDX2 has been reported in
intestinal-type gastric adenocarcinomas (Almeida et al, 2003), and
this is consistent with microarray data suggesting that a group of
intestine-specific genes are upregulated in gastric adenocarcino-
mas (Hippo et al, 2002). Collectively, the upregulation of two
CDX2-dependent genes, CDH17 and DEFA5, found in group 2,
represents a characteristic of intestinal cellular lineage that is, in
the stomach, implicated in the pathogenesis of intestinal-type
gastric adenocarcinoma.
In group 3, which consisted mainly of gastric adenocarcinomas,
only ARG2 exhibited a high level of expression. Arginase II has
been reported to be overexpressed in cancerous tissues in general
(Harris et al, 1983; Leu and Wang, 1992; Suer Gokmen et al, 1999;
del Ara et al, 2002; Porembska et al, 2003) and it is well established
that this gene is overexpressed in gastric adenocarcinomas (Wu
et al, 1996). Since ARG2 catalyses the conversion of arginine to
ornithine, a crucial metabolite in biosynthesis of glutamic acid,
proline and polyamines (Vockley et al, 1996), an increase in the
level of arginase may reflect accelerated metabolism due to cell
proliferation or tumour growth. Therefore, the overexpression of
ARG2 in adenocarcinomas, as defined in the present study, is
reasonable.
Genes other than those listed above were sporadically over-
expressed in a portion of the adenomas or adenocarcinomas,
although their expression levels were not significantly different
among the three groups. Eukaryotic elongation factor 1 gamma
is a subunit of EF1 and it is involved in RNA translation
(Janssen et al, 1991). Histone H2A.Z is a histone protein of the H2A
family and it is involved in DNA replication (Hatch and Bonner,
1990). Peripheral-type benzodiazepine receptor is involved in
mitochondrial cholesterol transport and proliferation, steroid
biosynthesis, and the stimulation of cell proliferation (Papado-
poulos, 1993). The overexpression of these genes is sporadic in
cancers of a variety of tissues (Lew et al, 1992; Miettinen et al,
1995; Mimori et al, 1995, 1996; Mathur et al, 1998; Hardwick et al,
1999; Venturini et al, 1999). Hierarchical clustering analysis
excluding EEF1G, H2AFZ and BZRP resulted in clusters identical
to that using the original nine genes, suggesting that these three
genes do not contribute to the molecular classification of three
groups, but may be involved in the common pathophysiology of
gastric tumours probably reflecting accelerated cell division or
metabolism.
Recent studies using a microarray analysis defined gene-
expression profiles of gastric adenocarcinoma (Hasegawa et al,
2002; Hippo et al, 2002). Interestingly, the spectra of genes that
were overexpressed in carcinoma tissues in these studies differ
significantly from the present study. The possible reason for this
discrepancy may be that these microarray studies analysed
advanced staged gastric carcinoma tissues. Since the samples used
for the extraction of relevant genes in the present study were low-
and high-grade adenomas, the detected genes may be over-
expressed specifically in adenoma tissues and not in adenocarci-
noma tissues. Thus, it seems reasonable that advanced staged
adenocarcinoma possess different gene-expression profiles from
those obtained in the present study. To elucidate the stage-specific
gene expressions, different stages of gastric tumours should be
analysed.
The results of the present study raise the possibility that the
expression profiles of specific genes may distinguish gastric
adenomas from adenocarcinomas and, more importantly, may
define subgroups of gastric adenomas that are unresolved by
conventional histopathology. Many studies have shown that gene-
expression profiles can be used to identify tumour subclasses
independent of histopathological diagnosis. Furthermore, these
tumour subclasses are frequently related to distinct cellular
lineages and are closely associated with prognosis or response to
treatment as shown in malignant lymphomas (Alizadeh et al, 2000;
Shipp et al, 2002) or breast cancer (Sorlie et al, 2001), confirming
the usefulness of expression profiling in the clinical practice of
cancer. Group 2, a mixture of low-and high-grade adenomas cases
with larger tumour sizes, exhibited gene-expression profiles
specific to the cellular lineage of intestinal epithelium that has
been implicated in an intestinal-type gastric adenocarcinoma
(Hippo et al, 2002). Thus, adenomas classified as group 2 tumours
may have a biological nature more closely related to adenocarci-
nomas in comparison to the adenomas classified in group1. On the
one hand, the expression profiles of CDH17, DEFA5 and other
CDX2 regulated genes may constitute specific tumour markers
for a distinct subgroup of gastric adenomas with a progressive
nature. On the other , gastric adenomas with expression profiles
similar to those of the smaller adenomas in group 1 may be
nonprogressive. There are no definite histological or clinical
markers to identify the progressive subgroup of adenomas.
Therefore, future applications of expression profiling of these
genes in biopsied samples may contribute to clinical practice and
may promote objective criteria for intervention, such as endo-
scopic mucosal resection.
However, there are several limitations in the present study
including that it is cross-sectional. There is no follow-up of the
adenoma cases and no data available on the prognoses or the
disease progression of the adenoma cases. Thus, the actual
prognostic value of this classification remains to be elucidated. A
longitudinal study is necessary to determine if adenomas classified
into group 2 actually develop into progressive diseases. These
types of studies are particularly difficult because lesions diagnosed
histologically as high-grade adenomas are resected endoscopically
without follow-up, as recommended in the literature (Lauwers and
Riddell, 1999). Another issue is that expression profiling is not in
complete accord with conventional histopathological classification,
(e.g. three high-grade adenomas classified into group 1 or two low-
and high-grade adenomas classified into group 3). Nevertheless,
we believe that more accurate discrimination will be achieved by
increasing the number of predictive genes involved in expression
profiling by extracting them through more comprehensive
investigations of gene expression, such as a large-scale DNA
microarray analysis. Alternatively, the detailed molecular and
pathological analyses of exceptional cases may provide additional
predictive information on the biological nature of gastric tumours.
All the three high-grade adenomas in group 1 were less than
20mm in diameter (8, 15 and 17mm) and an adenocarcinoma in
group 2 is the smallest T1/G1 tumour, raising the possibility
that such exceptional cases have particular biological character-
istics below the sensitivity of conventional histopathological
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expression profiling.
In conclusion, taking advantage of the expression profiles of a
set of genes identified in two cases of gastric adenoma, gastric
adenoma and adenocarcinoma can be classified into three groups
with distinct gene-expression patterns. One group consists
primarily of invasive adenocarcinoma, whereas the other two
groups consist of adenomas with potentially different biological
properties, as suggested by significantly different tumour sizes.
These findings add new insight into our understanding of the
molecular pathogenesis involved in the early stages of gastric
carcinogenesis, in developing specific tumour markers for
clinical practice and in designing potentially novel therapeutic
targets.
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